UnitedHealth: DOJ Medicare Advantage probes, the Amedisys antitrust case and the 2025 CEO change
UnitedHealth: DOJ Medicare Advantage probes, the Amedisys antitrust case and the 2025 CEO change: a public-record watch file compiled by Falling Shares Intelligence from filings and exchange disclosures, as of 2026-11-09. On 13 May 2025 UnitedHealth replaced its chief executive and suspended its 2025 financial outlook.
From the May 2025 chief executive change and guidance suspension to the July 2025 disclosure of criminal and civil DOJ requests, and the August 2025 Amedisys settlement: what the record shows and what the company says.
Falling Shares Intelligence, Edited by Wung Thomas, Editor-in-Chief. As of .
Summary
- On 13 May 2025 UnitedHealth replaced its chief executive and suspended its 2025 financial outlook.
- In July 2025 the company disclosed that it was complying with formal criminal and civil Justice Department requests about its Medicare business; it says it has full confidence in its practices.
- In August 2025 the DOJ settled its challenge to the Amedisys acquisition on condition of 164 divestitures, and the deal closed.
- A January 2026 Senate Judiciary staff report criticised its Medicare Advantage coding; the company disagrees. This desk found no public update on the DOJ probes.
Key figures
| DOJ requests disclosed | 24 Jul 2025 (Formal criminal and civil requests, per company filing as reported) |
|---|---|
| Divestitures required | 164 locations (About $528m annual revenue, 19 states) |
| Senate staff review | About 50,000 records (Report released 12 Jan 2026) |
Justice Department investigations
Press reports of a DOJ Medicare probe
The Wall Street Journal reported in May 2025 that the DOJ was investigating possible Medicare fraud at UnitedHealth, including how it used clinicians to gather diagnoses that support higher payments. At the time UnitedHealth said it had not been notified of any investigation. (May 2025)
Company discloses formal criminal and civil requests
In a securities filing UnitedHealth said it was complying with the Justice Department on formal criminal and civil requests concerning its Medicare programme, and that it had proactively contacted the DOJ after the media reports. It said it had launched its own review of its policies and had full confidence in its practices. (24 Jul 2025)
Senate Judiciary staff report on risk adjustment
Staff of Senator Chuck Grassley reviewed about 50,000 UnitedHealth records and concluded that the company aggressively games Medicare Advantage risk adjustment to inflate federal payments. UnitedHealth disagreed with the report's characterisation, saying its programmes comply with CMS requirements and have passed government audits. (12 Jan 2026)
Antitrust settlement and leadership change
DOJ settles its challenge to the Amedisys acquisition
The DOJ Antitrust Division and state co-plaintiffs challenged UnitedHealth's $3.3bn acquisition of Amedisys. The settlement required divestiture of 164 home health and hospice locations in 19 states (about $528m in annual revenue), a monitor, and a $1.1m civil penalty to be paid by Amedisys over false certification of its responses to federal document requests. (7 Aug 2025)
Amedisys acquisition closes
UnitedHealth closed its $3.3bn Amedisys acquisition one week after the DOJ settlement, making Amedisys a wholly owned subsidiary. (14 Aug 2025)
Chief executive replaced and guidance suspended
UnitedHealth announced that its chief executive was stepping down for personal reasons and that the chairman, a former chief executive, was returning to the role immediately. It suspended its 2025 financial guidance, citing rising medical care activity, after cutting profit guidance by almost 12% in April. Shares fell more than 10% in premarket trading. (13 May 2025)
Outcomes favourable to the company
Special master recommends judgment for UnitedHealth in a False Claims Act case
In a long-running False Claims Act case in the Central District of California over alleged Medicare Advantage overpayments of about $2bn, a court-appointed special master recommended summary judgment for UnitedHealth, finding the government lacked evidence on two essential elements. The DOJ asked the court to reject the report in April 2025. (3 Mar 2025)
Standard
This file compiles regulator and court documents, SEC filings as reported, company statements and published reporting about UnitedHealth Group Incorporated. Allegations are attributed to those who made them. An investigation is not a charge, a charge is not a finding, and nothing here is a finding of wrongdoing unless a competent authority has made one. UnitedHealth says it has full confidence in its practices and that its Medicare Advantage programmes comply with CMS requirements, and no charge against the company has been reported. Individuals are not named unless an official document names them and they are central; otherwise roles are used. This is news coverage for information only, not investment advice.
Right of reply
UnitedHealth Group Incorporated, and anyone named in a record cited here, can send corrections or comments to info@fallingshares.com (or directly to the Editor-in-Chief, Wung Thomas, at wungthomas@fallingshares.com). Material responses will be published alongside the relevant entry.